NeuroDerm Ltd. (NASDAQ:NDRM) Receives Average Recommendation of “Buy” from Analysts
Shares of NeuroDerm Ltd. (NASDAQ:NDRM) have earned a consensus rating of “Buy” from the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $45.80.
A number of equities analysts have issued reports on NDRM shares. Jefferies Group LLC restated a “buy” rating and set a $42.00 target price on shares of NeuroDerm in a research report on Friday, March 24th. Roth Capital set a $33.00 target price on shares of NeuroDerm and gave the stock a “buy” rating in a research report on Saturday, April 1st. Zacks Investment Research cut shares of NeuroDerm from a “buy” rating to a “hold” rating in a research report on Wednesday, April 5th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of NeuroDerm in a research report on Sunday, April 23rd. Finally, CIBC upgraded shares of NeuroDerm from a “market perform” rating to an “outperform” rating and set a $42.00 target price for the company in a research report on Wednesday, June 14th.
Several institutional investors have recently bought and sold shares of the stock. Menora Mivtachim Holdings LTD. raised its position in NeuroDerm by 17.9% in the first quarter. Menora Mivtachim Holdings LTD. now owns 681,556 shares of the biotechnology company’s stock worth $18,095,000 after buying an additional 103,582 shares in the last quarter. Nexthera Capital LP purchased a new position in NeuroDerm during the first quarter worth $7,646,000. OppenheimerFunds Inc. purchased a new position in NeuroDerm during the first quarter worth $7,588,000. FMR LLC purchased a new position in NeuroDerm during the first quarter worth $5,310,000. Finally, Bailard Inc. raised its position in NeuroDerm by 9.5% in the first quarter. Bailard Inc. now owns 109,000 shares of the biotechnology company’s stock worth $2,894,000 after buying an additional 9,500 shares in the last quarter. 52.33% of the stock is owned by institutional investors and hedge funds.
NeuroDerm (NASDAQ NDRM) traded up 2.35% on Monday, hitting $30.55. 42,847 shares of the company traded hands. The stock’s market cap is $804.63 million. NeuroDerm has a 12 month low of $15.20 and a 12 month high of $31.25. The stock’s 50-day moving average is $25.00 and its 200 day moving average is $24.84.
NeuroDerm (NASDAQ:NDRM) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.13. Equities research analysts expect that NeuroDerm will post ($2.02) earnings per share for the current fiscal year.
NeuroDerm Ltd. is an Israel-based clinical-stage pharmaceutical company. The Company is engaged in developing treatments for central nervous system (CNS) disorders, primarily Parkinson’s disease, as well as other CNS diseases. The Company’s Parkinson’s disease product candidates are drug-device combination products, with devices and varying levodopa (LD)/carbidopa (CD) or apomorphine concentrations and dosages.
Receive News & Ratings for NeuroDerm Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroDerm Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.